Navigation Links
Funding to tackle hospital superbugs

A novel approach to treating infectious diseases is being developed by researchers at Cardiff University.

Superbugs such as MRSA (Methicillin Resistant Staphylococcus Aureus) are resistant to one of more conventional antibiotic and require new therapies to aid the treatment of infection.

A team in the School of Medicine's Institute of Nephrology has been awarded £800,000 by the Wellcome Trust to commercially develop a protein based therapeutic to help treat infectious diseases.

Professor Nicholas Topley said: "Infectious diseases are a significant problem and the number of new antibiotics entering the market is falling rapidly whilst antibiotic resistance is increasing. The funding from the Wellcome Trust will help bring the pioneering new approaches developed in the School of Medicine to the market."

Research into the development of novel proteins discovered by the team led by Professor Topley and Dr Simon Jones has already identified new pathways that enhance the bodies natural defence mechanisms to promote the clearance of infection. The new approach has been named "Resolution Therapeutics" by the Cardiff researchers.

It is hoped that research in the School of Medicine will lead to the development of other drugs that modify host responses with the view to resolving infection and reducing inflammation in diseases such as arthritis.


'"/>

Source:Cardiff University


Page: 1

Related biology news :

1. Funding and bureaucracy, not access to journals, are chief obstacles to scientific productivity
2. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Smooth sailing: cruise ship virus tackled by UH, Baylor College of Medicine
5. Research project tackles regeneration gap
6. New antibacterials being developed to tackle MRSA superbug
7. New strategies to reduce hospital-aquired infections
8. Bacteria can survive for weeks on hospital surfaces
9. One in 14 men having a heart attack drive themselves to hospital
10. Minorities, uninsured less likely to receive care at high-volume hospitals
11. Controlling antibiotics and antibiotic resistance in hospitals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: